Your browser doesn't support javascript.
loading
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Boi, Michela; Todaro, Maria; Vurchio, Valentina; Yang, Shao Ning; Moon, John; Kwee, Ivo; Rinaldi, Andrea; Pan, Heng; Crescenzo, Ramona; Cheng, Mangeng; Cerchietti, Leandro; Elemento, Olivier; Riveiro, Maria E; Cvitkovic, Esteban; Bertoni, Francesco; Inghirami, Giorgio.
Afiliação
  • Boi M; Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
  • Todaro M; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Vurchio V; Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
  • Yang SN; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Moon J; Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
  • Kwee I; Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Rinaldi A; Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Pan H; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland.
  • Crescenzo R; Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland.
  • Cheng M; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
  • Cerchietti L; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland.
  • Elemento O; Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY, USA.
  • Riveiro ME; Institute for Precision Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Cvitkovic E; Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
  • Bertoni F; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Inghirami G; In Vitro Pharmacology, Merck Research Laboratory, Boston, MA, USA.
Oncotarget ; 7(48): 79637-79653, 2016 Nov 29.
Article em En | MEDLINE | ID: mdl-27793034
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Receptores Proteína Tirosina Quinases / Linfoma Anaplásico de Células Grandes / Resistencia a Medicamentos Antineoplásicos / Compostos Heterocíclicos com 3 Anéis / Acetanilidas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Receptores Proteína Tirosina Quinases / Linfoma Anaplásico de Células Grandes / Resistencia a Medicamentos Antineoplásicos / Compostos Heterocíclicos com 3 Anéis / Acetanilidas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Itália